Current Progress and Future Developments of Antibody Drug Conjugates
in Lung Cancer / 中国肺癌杂志
Chinese Journal of Lung Cancer
; (12): 468-476, 2022.
Article
in Zh
| WPRIM
| ID: wpr-939733
Responsible library:
WPRO
ABSTRACT
Antibody drug conjugates (ADCs) are a novel class of anti-cancer drugs, which combined the specificity of monoclonal antibodies with the cytotoxic palyload via the linkers. Many ADCs have not only verified impressive activity in a variety of cancers, including breast cancer and hematological system tumors, but also in lung cancer. The aim of this study was to provide informations for practice by summarizing the mechanism of action, clinical application and problems and challenges of ADCs.
.
Key words
Full text:
1
Database:
WPRIM
Main subject:
Immunoconjugates
/
Antineoplastic Agents, Immunological
/
Lung Neoplasms
/
Antibodies, Monoclonal
/
Neoplasms
/
Antineoplastic Agents
Limits:
Humans
Language:
Zh
Journal:
Chinese Journal of Lung Cancer
Year:
2022
Document type:
Article